## Sovaldi® (Sofosbuvir) & Ribavirin 16 week Treatment Checklist

Prior to Treatment		
Labs	Decree of the Control	LL. V
immediately prior	: Pregnancy test (if applica	ble )
	Uric Acid	
Within 1 month:	CBC with differential	
		start treatment; consult Liver Disease Specialist)
	PT/INR	
Within 3 months:		
	Genotype confirmation	
Within 6 months:		
	TSH	
	A1C or Fasting Glucose	
	Vitamin D 250H (treat if o	deficient)
	HIV screening	
Miscellaneous		
	status/screening if not done	
	status/screening if not done	
PHQ-9 base	eline	
AUDIT-C		
Symptoms	Inventory baseline	
Week 2		
CBC		3 months post treatment
CMP <sup>1</sup>		CBC
Symptoms	Inventory	Liver Function Tests
147 I. 4		HCV RNA
Week 4		PHQ-9
HCV RNA		
CBC		Nurse follow-up in clinic or by phone:
CMP <sup>1</sup>		Symptoms Inventory
Symptoms		Managing side effects
Pregnancy	test (if applicable)	Medication adherence discussion
Marks 0 0 13		Alcohol intake
Weeks 8 & 12		Birth control reminder
CBC CMP <sup>1</sup>		Refill reminder
	Inventory	
Symptoms		
Pregnancy	test (if applicable)	
Week 16		
HCV RNA		
CBC		
Symptoms	Inventory	
	test (if applicable)	
' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '	toot (ii appiioanic)	

1- If GFR <30, consult Liver Disease Specialist.

## Sovaldi® (Sofosbuvir) & Ribavirin 16 week Lab Tracking Form

General Patient Information	Pre-Treatment Lab Results	Medication Regimen				
Name:	HCV RNA:	1- Sofosbuvir 400mg 1 tablet PO daily. Do not change dose.				
DOB:/	Genotype: HIV: TSH:	2- Ribavirin: mg/day PO divided into 2 doses. Take with breakfast & dinner.  ≥75kg = 1200mg/day <75kg = 1000mg/day				
MRN:	Vit D 25OH: AFP: GFR*:	**Dose Reduction/Date:/				
Phone #:	PT/INR: A1C/Glucose:	**Additional Dose Change/Date:/				
Treatment Start Date:		**Consult ANTHC Liver Disease & Hepatitis Specialists for further guidance about dose changes.				

Completed Treatment											5110.0	1161/ 2014	Weight	Pregnancy
Week	Lab Date	Hgb	Hct	WBC	PLT	ALT	AST	Alk Phos	Total Bili	Creat/ GFR	PHQ-9 (Specified weeks)	HCV RNA (Specified weeks)	(kg)	Test
Pre-Treatment														
Treatment Start														
Week 0											PHQ-9	HCV RNA		
optional														
Week 2														
optional														
Week 4												HCV RNA		
optional														
optional														
Week 8														
optional														
optional														
Week 12											PHQ-9	HCV RNA		
optional														
optional														
Week 16											PHQ-9	HCV RNA		
3 months post treatment											PHQ-9	HCV RNA		

Labs recommended for each follow up visit: CBC, CMP, pregnancy test (females of childbearing age), and HCV RNA as specified.

Please note the following critical values. These may require modification of dosage or discontinuation of causative med. Contact ANTHC Liver Disease Specialists with any questions.

\*GFR <30 If GFR is <30, do not start treatment; consult with Liver Disease Specialists.

Hgb <10.0 gm/dL If hemoglobin drops below 10, reduce ribavirin dose to 600mg (refer to Sofosbuvir package insert). If hemoglobin <8.5, hold ribavirin & consult ANTHC Liver Disease Specialists.

GFR <50 If GFR is <50, decrease ribavirin dose (refer to ribavirin package insert) and consult ANTHC Liver Disease Specialists.

PLTs <50 K/uL If platelet count drops below 50, consult ANTHC Liver Disease Specialists.